Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2016 (2016), Article ID 5378567, 11 pages
http://dx.doi.org/10.1155/2016/5378567
Research Article

Overexpression of β-Catenin Induces Cisplatin Resistance in Oral Squamous Cell Carcinoma

1Department of Oral and Maxillofacial Surgery, Guanghua School and Hospital of Stomatology, Sun Yat-sen University, Guangzhou 510055, China
2Guangdong Key Laboratory of Stomatology, Sun Yat-sen University, Guangzhou 510074, China
3Department of Oral Pathology, Guanghua School and Hospital of Stomatology, Sun Yat-sen University, Guangzhou 510055, China

Received 2 May 2016; Accepted 22 June 2016

Academic Editor: Antonello Merlino

Copyright © 2016 Long Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Ferlay, I. Soerjomataram, R. Dikshit et al., “Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012,” International Journal of Cancer, vol. 136, no. 5, pp. E359–E386, 2015. View at Publisher · View at Google Scholar · View at Scopus
  2. J.-P. Machiels, M. Lambrecht, F.-X. Hanin et al., “Advances in the management of squamous cell carcinoma of the head and neck,” F1000Prime Reports, vol. 6, article 44, 2014. View at Publisher · View at Google Scholar · View at Scopus
  3. R. I. Haddad and D. M. Shin, “Recent advances in head and neck cancer,” New England Journal of Medicine, vol. 359, no. 11, pp. 1096–1154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Argiris, M. V. Karamouzis, D. Raben, and R. L. Ferris, “Head and neck cancer,” The Lancet, vol. 371, no. 9625, pp. 1695–1709, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. D. M. Parkin, F. Bray, J. Ferlay, and P. Pisani, “Estimating the world cancer burden: Globocan 2000,” International Journal of Cancer, vol. 94, no. 2, pp. 153–156, 2001. View at Publisher · View at Google Scholar · View at Scopus
  6. I. Chiba, “Prevention of betel quid chewers' oral cancer in the asian-pacific area,” Asian Pacific Journal of Cancer Prevention, vol. 2, no. 4, pp. 263–269, 2001. View at Google Scholar · View at Scopus
  7. J. Ferlay, H.-R. Shin, F. Bray, D. Forman, C. D. Mathers, and D. M. Parkin, “Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008,” International Journal of Cancer, vol. 127, no. 12, pp. 2893–2917, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Siegel, E. Ward, O. Brawley, and A. Jemal, “Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths,” CA Cancer Journal for Clinicians, vol. 61, no. 4, pp. 212–236, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Jemal, R. Siegel, E. Ward, Y. Hao, J. Xu, and M. J. Thun, “Cancer statistics, 2009,” CA: A Cancer Journal for Clinicians, vol. 59, no. 4, pp. 225–249, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-P. Pignon, A. le Maître, E. Maillard, and J. Bourhis, “Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients,” Radiotherapy and Oncology, vol. 92, no. 1, pp. 4–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. D. P. Kelsen, K. A. Winter, L. L. Gunderson et al., “Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3719–3725, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. E. Ancona, A. Ruol, C. Castoro et al., “First-line chemotherapy improves the resection rate and long-term survival of locally advanced (T4, any N, M0) squamous cell carcinoma of the thoracic esophagus: final report on 163 consecutive patients with 5-year follow-up,” Annals of Surgery, vol. 226, no. 6, pp. 714–724, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. C. Domenge, C. Hill, J. L. Lefebvre et al., “Randomized trial of neoadjuvant chemotherapy in oropharyngeal carcinoma. French Groupe d’Etude des Tumeurs de la Tete et du Cou (GETTEC),” British Journal of Cancer, vol. 83, pp. 1594–1598, 2000. View at Publisher · View at Google Scholar
  14. J. Bernier, C. Domenge, M. Ozsahin et al., “Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer,” The New England Journal of Medicine, vol. 350, no. 19, pp. 1945–1952, 2004. View at Publisher · View at Google Scholar · View at Scopus
  15. J. S. Cooper, T. F. Pajak, A. A. Forastiere et al., “Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck,” The New England Journal of Medicine, vol. 350, no. 19, pp. 1937–2019, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. Y. Yu, G. Ramena, and R. C. Elble, “The role of cancer stem cells in relapse of solid tumors,” Frontiers in Bioscience-Elite, vol. 4, no. 4, pp. 1528–1541, 2012. View at Google Scholar · View at Scopus
  17. D. Wang and S. J. Lippard, “Cellular processing of platinum anticancer drugs,” Nature Reviews Drug Discovery, vol. 4, no. 4, pp. 307–320, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Yoshioka, M. L. King, S. Ran et al., “WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway,” Molecular Cancer Research, vol. 10, no. 3, pp. 469–482, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. D. J. Stewart, “Mechanisms of resistance to cisplatin and carboplatin,” Critical Reviews in Oncology/Hematology, vol. 63, no. 1, pp. 12–31, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. R. C. Arend, A. I. Londoño-Joshi, J. M. Straughn Jr., and D. J. Buchsbaum, “The Wnt/β-catenin pathway in ovarian cancer: a review,” Gynecologic Oncology, vol. 131, no. 3, pp. 772–779, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Yeung, M. T. Esposito, A. Gandillet et al., “β-Catenin mediates the establishment and drug resistance of MLL leukemic stem cells,” Cancer Cell, vol. 18, no. 6, pp. 606–618, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. R. C. Arend, A. I. Londoño-Joshi, R. S. Samant et al., “Inhibition of Wnt/β-catenin pathway by niclosamide: a therapeutic target for ovarian cancer,” Gynecologic Oncology, vol. 134, no. 1, pp. 112–120, 2014. View at Publisher · View at Google Scholar · View at Scopus
  23. B. Zhang, M. Liu, H.-K. Tang et al., “The expression and significance of MRP1, LRP, TOPOIIβ, and BCL2 in tongue squamous cell carcinoma,” Journal of Oral Pathology and Medicine, vol. 41, no. 2, pp. 141–148, 2012. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Lü, L. Zhang, M. S. M. Wai, D. T. W. Yew, and J. Xu, “Exocytosis of MTT formazan could exacerbate cell injury,” Toxicology in Vitro, vol. 26, no. 4, pp. 636–644, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. M. Flahaut, R. Meier, A. Coulon et al., “The Wnt receptor FZD1 mediates chemoresistance in neuroblastoma through activation of the Wnt/β-catenin pathway,” Oncogene, vol. 28, no. 23, pp. 2245–2256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. T. Ohigashi, R. Mizuno, J. Nakashima, K. Marumo, and M. Murai, “Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells,” Prostate, vol. 62, no. 1, pp. 61–68, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. H. J. Broxterman, J. Lankelma, and K. Hoekman, “Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences,” Drug Resistance Updates, vol. 6, no. 3, pp. 111–127, 2003. View at Publisher · View at Google Scholar · View at Scopus
  28. E. R. Jamieson and S. J. Lippard, “Structure, recognition, and processing of cisplatin-DNA adducts,” Chemical Reviews, vol. 99, no. 9, pp. 2467–2498, 1999. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Eckstein, K. Servan, B. Hildebrandt et al., “Hyperactivation of the insulin-like growth factor receptor I signaling pathway Is an essential event for cisplatin resistance of ovarian cancer cells,” Cancer Research, vol. 69, no. 7, pp. 2996–3003, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. K. Kohno, T. Uchiumi, I. Niina et al., “Transcription factors and drug resistance,” European Journal of Cancer, vol. 41, no. 16, pp. 2577–2586, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. N. Chikazawa, H. Tanaka, T. Tasaka et al., “Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells,” Anticancer Research, vol. 30, no. 6, pp. 2041–2048, 2010. View at Google Scholar · View at Scopus
  32. Z. H. Siddik, “Cisplatin: mode of cytotoxic action and molecular basis of resistance,” Oncogene, vol. 22, no. 47, pp. 7265–7279, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. M. T. Furlong and P. J. Morin, “Rare activation of the TCF/β-catenin pathway in ovarian cancer,” Gynecologic Oncology, vol. 77, no. 1, pp. 97–104, 2000. View at Publisher · View at Google Scholar · View at Scopus
  34. S. M. Sillanpää, M. A. Anttila, K. A. Voutilainen et al., “Prognostic significance of matrix metalloproteinase-7 in epithelial ovarian cancer and its relation to β-catenin expression,” International Journal of Cancer, vol. 119, no. 8, pp. 1792–1799, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. S. Condello, C. A. Morgan, S. Nagdas et al., “β-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids,” Oncogene, vol. 34, no. 18, pp. 2297–2308, 2015. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Van Noort and H. Clevers, “TCF transcription factors, mediators of Wnt-signaling in development and cancer,” Developmental Biology, vol. 244, no. 1, pp. 1–8, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. C. G. Ferreira, M. Epping, F. A. Kruyt, and G. Giaccone, “Apoptosis: target of cancer therapy,” Clinical Cancer Research, vol. 8, no. 7, pp. 2024–2034, 2003. View at Google Scholar
  38. Y. Zhang, B. Z. Liu, Q. Y. Zhao, T. Hou, and X. Huang, “Nuclear localizaiton of β-catenin is associated with poor survival and chemo-/radioresistance in human cervical squamous cell cancer,” International Journal of Clinical and Experimental Pathology, vol. 7, no. 7, pp. 3908–3917, 2014. View at Google Scholar · View at Scopus
  39. D.-F. Yu, F.-R. Wu, Y. Liu, H. Liu, and Q. Xia, “Bcl-2 gene silence enhances the sensitivity toward 5-Fluorouracil in gastric adenocarcinoma cells,” Biomedicine and Pharmacotherapy, vol. 67, no. 7, pp. 615–619, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. H. V. Jagani, V. R. Josyula, V. R. Palanimuthu, R. C. Hariharapura, and S. S. Gang, “Improvement of therapeutic efficacy of PLGA nanoformulation of siRNA targeting anti-apoptotic Bcl-2 through chitosan coating,” European Journal of Pharmaceutical Sciences, vol. 48, no. 4-5, pp. 611–618, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  42. K. Kato, S. Kawashiri, K. Yoshizawa, H. Kitahara, and E. Yamamoto, “Apoptosis-associated markers and clinical outcome in human oral squamous cell carcinomas,” Journal of Oral Pathology and Medicine, vol. 37, no. 6, pp. 364–371, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. F. J. Sharom, “The P-glycoprotein efflux pump: how does it transport drugs?” Journal of Membrane Biology, vol. 160, no. 3, pp. 161–175, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. E. M. Leslie, R. G. Deeley, and S. P. C. Cole, “Toxicological relevance of the multidrug resistance protein 1, MRP1 (ABCC1) and related transporters,” Toxicology, vol. 167, no. 1, pp. 3–23, 2001. View at Publisher · View at Google Scholar · View at Scopus
  45. V. Velingkar and V. Dandekar, “Modulation of P-glycoprotein mediated multidrug resistance (MDR) in cancer using chemosensitizers,” International Journal of Pharmaceutical Sciences and Research, vol. 1, pp. 104–111, 2010. View at Google Scholar
  46. T. Ozben, “Mechanisms and strategies to overcome multiple drug resistance in cancer,” FEBS Letters, vol. 580, no. 12, pp. 2903–2909, 2006. View at Publisher · View at Google Scholar · View at Scopus